MYX · ASX

Mayne Pharma Group Ltd. (ASX:MYX)

AU$5.2

 0.15 (2.97%)
ASX:Live
13/06/2025 04:10:38 PM
Short Sold <-1 over the month HALO Small HALO Ords GROWTH AUS EMA 125 Breakdown +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

MYX Overview

MYX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Weak

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Neutral

Growth

Earnings

Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About MYX

Website

Mayne Pharma Group Ltd.

Telephone

61.8.8209.2666

Address

Salisbury South 1538 Main North Road Salisbury, South Australia (SA) 5106

Description

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.

MYX Price Chart

Key Stats

Market Cap

AU$415.17M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

100%

Ex Dividend Date (est.)

18-Jan-23

Market Data

52 weeks range

Low 3.74 - 7.31

Trade Value (12mth)

AU$636,764.00

1 week

0.6%

1 month

-25.63%

YTD

5.21%

1 year

12.72%

All time high

37.10

Key Fundamentals

EPS 3 yr Growth

-17.50%

EBITDA Margin

-2.40%

Operating Cashflow

-$10m

Free Cash Flow Return

-1.70%

ROIC

-29.20%

Interest Coverage

-2.00

Quick Ratio

1.20

Other Data

Shares on Issue (Fully Dilluted)

81m

HALO Sector

Healthcare

Next Company Report Date

21-Aug-25

Ex Dividend Date (est.)

18-Jan-23

Next Dividend Pay Date (est.)

27-Jan-23

Reporting Currency

AUD

Short Sell (% of issue)

1.59

MYX Announcements

Latest Announcements

Date Announcements

11 June 25

Becoming a substantial holder from MS

×

Becoming a substantial holder from MS

11 June 25

Change in substantial holding from MUFG

×

Change in substantial holding from MUFG

11 June 25

Change in substantial holding

×

Change in substantial holding

10 June 25

Becoming a substantial holder from MUFG

×

Becoming a substantial holder from MUFG

10 June 25

Change in substantial holding

×

Change in substantial holding

10 June 25

Change in substantial holding

×

Change in substantial holding

10 June 25

Change in substantial holding

×

Change in substantial holding

06 June 25

Becoming a substantial holder

×

Becoming a substantial holder

05 June 25

Supplementary Scheme Booklet

×

Supplementary Scheme Booklet

04 June 25

Change in substantial holding

×

Change in substantial holding

04 June 25

Update on Scheme of Arrangement with Cosette

×

Update on Scheme of Arrangement with Cosette

04 June 25

Mayne Pharma receives purported notice to terminate SID

×

Mayne Pharma receives purported notice to terminate SID

02 June 25

Update on US legal proceeding with TherapeuticsMD Inc

×

Update on US legal proceeding with TherapeuticsMD Inc

02 June 25

Change in substantial holding

×

Change in substantial holding

27 May 25

Change in substantial holding

×

Change in substantial holding

27 May 25

Change in substantial holding

×

Change in substantial holding

22 May 25

Response to ASX Aware Letter

×

Response to ASX Aware Letter

21 May 25

Update on Scheme with Cosette

×

Update on Scheme with Cosette

20 May 25

Dispatch of Scheme Booklet

×

Dispatch of Scheme Booklet

20 May 25

Change in substantial holding

×

Change in substantial holding

19 May 25

Trading Halt

×

Trading Halt

15 May 25

Court approves convening of scheme meeting

×

Court approves convening of scheme meeting

15 May 25

ASIC registration of Mayne Pharma scheme booklet

×

ASIC registration of Mayne Pharma scheme booklet

14 May 25

Pause in Trade

×

Pause in Trade

14 May 25

Response to ASX Price Query

×

Response to ASX Price Query

14 May 25

Mayne Pharma responds to speculation on FDA untitled letter

×

Mayne Pharma responds to speculation on FDA untitled letter

MYX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -3.42 -3.85 -2.19 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -3.42 -3.67 -2.19 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.8 -12.7 43.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.09 -2.26 0.06 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.32 -1.12 -0.22 Lock Lock Lock
     Growth % Lock Lock Lock Lock -112.7 -2,475.7 102.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -6.5 -25.5 -4.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.6 N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 6.19 7.60 5.59 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 1.34 0.20 -1.41 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.5 -84.7 -787.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 82 86 80 Lock Lock Lock
Basic m Lock Lock Lock Lock 82 82 80 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 157 184 388 Lock Lock Lock
     Growth % Lock Lock Lock Lock -60.8 16.8 111.6 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 146 213 237 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 24 27 159 Lock Lock Lock
     Growth % Lock Lock Lock Lock -81.3 13.0 492.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock 15.1 14.6 41.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 85 85 59 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -67 -121 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -195.9 -81.4 92.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -42.4 -65.9 -2.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 55 65 68 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -122 -186 -78 Lock Lock Lock
     Growth % Lock Lock Lock Lock -9,042.0 -53.0 58.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -77.6 -101.6 -20.0 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -146 -270 -190 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 75 48 -21 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -281 -316 -174 Lock Lock Lock
     Growth % Lock Lock Lock Lock -35.0 -12.5 44.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -179.0 -172.4 -44.9 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -17 -43 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 12 220 21 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -29 473 53 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 37 -431 -26 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -27 -51 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -188.3 -93.3 66.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.2 -0.3 -0.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 22 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 97 229 152 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 1,303 1,248 1,143 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 6 33 35 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 317 -182 -113 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 765 614 689 Lock Lock Lock
Equity $m Lock Lock Lock Lock 546 634 454 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 552 667 489 Lock Lock Lock
     Growth % Lock Lock Lock Lock -48.0 21.0 -26.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.6 -25.4 -15.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -51.5 -49.9 -38.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -11.8 -22.6 -13.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -26.0 -51.3 -29.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -2.1 -7.0 -1.7 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -5.8 -11.6 -2.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -4.7 1.5 12.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 58.0 -28.6 -24.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 0.8 1.8 1.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.6 1.5 1.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 19.0 41.4 32.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -2.6 -13.9 -3.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.7 0.7 1.9 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.3 1.6 2.9 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.8 2.6 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 40.5 17.4 5.4 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.3 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.3 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -92.6 -146.9 -48.9 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -11.2 -21.6 -16.6 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.6 -25.4 -15.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 2.4 2.0 2.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -51.5 -49.9 -38.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -51.5 -49.9 -38.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 289.2 223.1 125.2 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 553.2 489.6 196.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 842.4 712.7 321.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 144.9 133.7 43.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 697.5 579.1 277.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

18-Jan-23

DIV Yield

N/A

Franking Level

100%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

1.59%

Value ($M)

6

Prior Change

N/A

7 Day Change

N/A

1 Month Change

-1.40%

3 Month Change

1.60%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

MYX Shortsell

Frequently Asked Questions

The current share price of Mayne Pharma Group Ltd. (MYX:ASX) is AU$5.2.
The 52-week high share price for Mayne Pharma Group Ltd. (MYX:ASX) is AU$7.31.
The 52-week low share price for Mayne Pharma Group Ltd. (MYX:ASX)? is AU$3.74.
Mayne Pharma Group Ltd. (MYX:ASX) does not pay a dividend.
The last dividend payment of Mayne Pharma Group Ltd. (MYX:ASX) is AU$0.03.
Mayne Pharma Group Ltd. (MYX:ASX) has a franking level of 100.0%.
Mayne Pharma Group Ltd. (MYX:ASX) is classified in the Healthcare.
The current P/E ratio for Mayne Pharma Group Ltd. (MYX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.